Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2164) 2164
Book Review (283) 283
Publication (161) 161
Conference Proceeding (7) 7
Book Chapter (4) 4
Dissertation (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1949) 1949
humans (1831) 1831
topotecan (1470) 1470
oncology (1447) 1447
female (1378) 1378
topotecan - administration & dosage (960) 960
middle aged (897) 897
aged (824) 824
chemotherapy (802) 802
adult (792) 792
male (791) 791
antineoplastic combined chemotherapy protocols - therapeutic use (708) 708
cancer (634) 634
ovarian neoplasms - drug therapy (458) 458
treatment outcome (455) 455
cisplatin (410) 410
camptothecin - analogs & derivatives (399) 399
drug administration schedule (397) 397
animals (396) 396
topotecan - adverse effects (390) 390
antineoplastic agents - administration & dosage (389) 389
pharmacology & pharmacy (366) 366
antineoplastic agents - therapeutic use (363) 363
paclitaxel (362) 362
lung neoplasms - drug therapy (328) 328
topotecan - therapeutic use (324) 324
antineoplastic combined chemotherapy protocols - adverse effects (312) 312
ovarian cancer (303) 303
carcinoma (301) 301
neoplasm recurrence, local - drug therapy (298) 298
dose-response relationship, drug (277) 277
mice (274) 274
camptothecin (270) 270
camptothecin - administration & dosage (257) 257
aged, 80 and over (253) 253
cisplatin - administration & dosage (249) 249
paclitaxel - administration & dosage (247) 247
trial (247) 247
antineoplastic agents - adverse effects (241) 241
care and treatment (240) 240
infusions, intravenous (240) 240
phase-ii (234) 234
neoplasms - drug therapy (227) 227
antineoplastic combined chemotherapy protocols - administration & dosage (223) 223
topotecan - pharmacokinetics (221) 221
carboplatin (211) 211
irinotecan (211) 211
carboplatin - administration & dosage (210) 210
obstetrics & gynecology (209) 209
etoposide (207) 207
drug resistance, neoplasm (206) 206
disease-free survival (203) 203
pharmacokinetics (203) 203
research (202) 202
solid tumors (200) 200
phase-i (198) 198
antineoplastic agents - pharmacokinetics (192) 192
cell line, tumor (184) 184
medicine & public health (184) 184
therapy (184) 184
survival rate (179) 179
child (173) 173
topoisomerase i inhibitors (171) 171
ovarian neoplasms - pathology (170) 170
topotecan - pharmacology (170) 170
neoplasm staging (166) 166
cyclophosphamide (165) 165
etoposide - administration & dosage (165) 165
child, preschool (161) 161
adolescent (160) 160
antineoplastic agents (158) 158
survival analysis (158) 158
doxorubicin - administration & dosage (155) 155
tumors (154) 154
administration, oral (153) 153
retrospective studies (152) 152
cell lung-cancer (149) 149
drug therapy (149) 149
hematology (149) 149
hematology, oncology and palliative medicine (149) 149
lung neoplasms - pathology (148) 148
antineoplastic agents - pharmacology (146) 146
camptothecin - therapeutic use (146) 146
combination (142) 142
analysis (141) 141
antimitotic agents (141) 141
carcinoma, small cell - drug therapy (141) 141
doxorubicin (141) 141
gynecologic-oncology-group (140) 140
topoisomerase-i (137) 137
clinical trials (136) 136
combined modality therapy (133) 133
prognosis (132) 132
toxicity (132) 132
deoxycytidine - analogs & derivatives (129) 129
camptothecin - adverse effects (125) 125
camptothecin - pharmacokinetics (121) 121
pharmacology/toxicology (120) 120
salvage therapy (119) 119
gemcitabine (115) 115
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2112) 2112
French (15) 15
Japanese (12) 12
Chinese (11) 11
Italian (8) 8
Hungarian (4) 4
Polish (3) 3
Portuguese (2) 2
German (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
by Pujade-Lauraine, Eric and Pujade-Lauraine, Eric and Hilpert, Felix and Hilpert, Felix and Weber, Béatrice and Weber, Béatrice and Reuss, Alexander and Reuss, Alexander and Poveda, Andres and Poveda, Andres and Kristensen, Gunnar and Kristensen, Gunnar and Sorio, Roberto and Sorio, Roberto and Vergote, Ignace and Vergote, Ignace and Witteveen, Petronella and Witteveen, Petronella and Bamias, Aristotelis and Bamias, Aristotelis and Pereira, Deolinda and Pereira, Deolinda and Wimberger, Pauline and Wimberger, Pauline and Oaknin, Ana and Oaknin, Ana and Mirza, Mansoor Raza and Mirza, Mansoor Raza and Follana, Philippe and Follana, Philippe and Bollag, David and Bollag, David and Ray-Coquard, Isabelle and Ray-Coquard, Isabelle
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Purpose In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first... 
PEGYLATED LIPOSOMAL DOXORUBICIN | SINGLE-AGENT | ONCOLOGY | TOPOTECAN | EPITHELIAL OVARIAN | PRIMARY PERITONEAL | PROGRESSION | PACLITAXEL | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Polyethylene Glycols - adverse effects | Drug Resistance, Neoplasm | Polyethylene Glycols - therapeutic use | Organoplatinum Compounds - pharmacology | Bevacizumab | Antibodies, Monoclonal, Humanized - administration & dosage | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Paclitaxel - adverse effects | Topotecan - adverse effects | Topotecan - therapeutic use | Paclitaxel - therapeutic use | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Aged | Doxorubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study
by Pignata, Sandro and Scambia, Giovanni and Bologna, Alessandra and Signoriello, Simona and Vergote, Ignace B and Wagner, Uwe and Lorusso, Domenica and Murgia, Viviana and Sorio, Roberto and Ferrandina, Gabriella and Sacco, Cosimo and Cormio, Gennaro and Breda, Enrico and Cinieri, Saverio and Natale, Donato and Mangili, Giorgia and Pisano, Carmela and Cecere, Sabrina Chiara and Di Napoli, Marilena and Salutari, Vanda and Raspagliesi, Francesco and Arenare, Laura and Bergamini, Alice and Bryce, Jane and Daniele, Gennaro and Piccirillo, Maria Carmela and Gallo, Ciro and Perrone, Francesco
Journal of Clinical Oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3347 - 3353
Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous... 
PEGYLATED LIPOSOMAL DOXORUBICIN | THERAPY | SOLID TUMORS | CISPLATIN | ONCOLOGY | BEVACIZUMAB | GUIDELINES | PHASE-3 TRIAL | DOUBLE-BLIND | TREBANANIB | CARCINOMA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ovarian Neoplasms - mortality | Early Termination of Clinical Trials | Time Factors | Dioxoles - administration & dosage | Doxorubicin - analogs & derivatives | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Treatment Outcome | Tetrahydroisoquinolines - administration & dosage | Disease Progression | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Topotecan - administration & dosage | Aged | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
by Alex Sparreboom and Antonio C. Wolff and Ron H.J. Mathijssen and Etienne Chatelut and Eric K. Rowinsky and Jaap Verweij and Sharyn D. Baker
Journal of Clinical Oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 30, pp. 4707 - 4713
textabstractPurpose: Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | BREAST-CANCER | ADJUVANT CHEMOTHERAPY | HUMAN PLASMA | PHARMACOKINETICS | ONCOLOGY | BODY-SURFACE AREA | DIOXOLANE NUCLEOSIDE ANALOG | DOXORUBICIN | IRINOTECAN | PACLITAXEL | Body Mass Index | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Body Weight | Obesity - drug therapy | Area Under Curve | Body Size | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Carboplatin - administration & dosage | Cytosine - administration & dosage | Metabolic Clearance Rate | Cisplatin - administration & dosage | Obesity - metabolism | Taxoids - administration & dosage | Adolescent | Topotecan - administration & dosage | Camptothecin - administration & dosage | Dioxolanes - administration & dosage | Body Surface Area | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
by Baker, Sharyn D and Verweij, Jaap and Rowinsky, Eric K and Donehower, Ross C and Schellens, Jan H.M and Grochow, Louise B and Sparreboom, Alex
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis | Studies | Medical research | Adults | History | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma
by García-Sanz, R and González-López, T.J and Vázquez, L and Hermida, G and Graciani, I.F and San Miguel, J.F
European Journal of Haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report... 
Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Hodgkin's lymphoma | dexamethasone | refractory disease | THERAPY | thalidomide | RECURRENT | transplantation | DISEASE | cyclophosphamide | VINBLASTINE | PATIENT | HEMATOLOGY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
by Stockler, Martin R and Stockler, Martin R and Hilpert, Felix and Hilpert, Felix and Friedlander, Michael and Friedlander, Michael and King, Madeleine T and King, Madeleine T and Wenzel, Lari and Wenzel, Lari and Lee, Chee Khoon and Lee, Chee Khoon and Joly, Florence and Joly, Florence and de Gregorio, Nikolaus and De Gregorio, Nikolaus and Arranz, José Angel and Arranz, José Angel and Mirza, Mansoor Raza and Mirza, Mansoor Raza and Sorio, Roberto and Sorio, Roberto and Freudensprung, Ulrich and Freudensprung, Ulrich and Sneller, Vesna and Sneller, Vesna and Hales, Gill and Hales, Gill and Pujade-Lauraine, Eric and Pujade-Lauraine, Eric
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1309 - 1316
Purpose To determine the effects of bevacizumab on patient-reported outcomes (PROs; secondary end point) in the AURELIA trial. Patients and Methods Patients... 
INSTITUTE | QUALITY-OF-LIFE | ONCOLOGY | CLINICAL-TRIALS | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Drug Resistance, Neoplasm | Polyethylene Glycols - therapeutic use | Organoplatinum Compounds - pharmacology | Bevacizumab | Antibodies, Monoclonal, Humanized - administration & dosage | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Self Report | Paclitaxel - adverse effects | Topotecan - adverse effects | Treatment Outcome | Topotecan - therapeutic use | Paclitaxel - therapeutic use | Polyethylene Glycols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Aged | Doxorubicin - adverse effects | Index Medicus | Gync20 | Psc7 | Gync19 | ORIGINAL REPORTS | Psc13
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Topotecan–tamoxifen duple PLGA polymeric nanoparticles: Investigation of in vitro, in vivo and cellular uptake potential
by Khuroo, Tahir and Verma, Devina and Talegaonkar, Sushama and Padhi, Santwana and Panda, Amulya K and Iqbal, Zeenat
International Journal of Pharmaceutics, ISSN 0378-5173, 10/2014, Volume 473, Issue 1-2, pp. 384 - 394
The dual drug loaded poly( -lactic-co-glycolic acid) (PLGA ) nanoparticles (TOP–TAM NPs ) concurrently delivering topotecan hydrochloride (TOP ) and tamoxifen... 
Nanoparticles | P-glycoprotein | Topotecan | Bioavailability | Tamoxifen | MCF-7 | BREAST-CANCER | PHARMACOLOGY & PHARMACY | Lactic Acid - chemistry | Nanoparticles - chemistry | Rats, Wistar | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Topoisomerase I Inhibitors - administration & dosage | Drug Carriers - administration & dosage | Tamoxifen - administration & dosage | Drug Carriers - chemistry | Intestinal Absorption | Topotecan - chemistry | Animals | Biological Transport | MCF-7 Cells | Polyglycolic Acid - chemistry | Tamoxifen - chemistry | Topotecan - administration & dosage | Female | Nanoparticles - administration & dosage | Antineoplastic Agents, Hormonal - chemistry | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Topoisomerase I Inhibitors - chemistry | Investigations | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs
by Reddy, Joseph A and Dorton, Ryan and Bloomfield, Alicia and Nelson, Melissa and Vetzel, Marilynn and Guan, John and Leamon, Christopher P
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 8, pp. 2104 - 2114
Purpose: When evaluated in patients with ovarian and other cancer, vintafolide (EC145), a potent folate-targeted vinca alkaloid conjugate, displayed a toxicity... 
OVEREXPRESSION | ONCOLOGY | FOLATE RECEPTOR EXPRESSION | PHASE-II | CONJUGATE | TISSUES | INHIBITORS | ANTITUMOR-ACTIVITY | CELL-LINES | CANCER | EPITHELIAL OVARIAN-CARCINOMA | Folic Acid - pharmacology | Paclitaxel - pharmacology | Taxoids - pharmacology | Humans | Antineoplastic Agents - administration & dosage | Folic Acid - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Vinca Alkaloids - administration & dosage | Vinca Alkaloids - pharmacology | Camptothecin - administration & dosage | Mice, Inbred DBA | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Folic Acid - analogs & derivatives | Topotecan - pharmacology | Carboplatin - administration & dosage | Treatment Outcome | Cisplatin - pharmacology | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Topotecan - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | HeLa Cells | Carboplatin - pharmacology | Neoplasms - pathology | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Doxorubicin - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma
by Federico, Sara M and McCarville, M. Beth and Shulkin, Barry L and Sondel, Paul M and Hank, Jacquelyn A and Hutson, Paul and Meagher, Michael and Shafer, Aaron and Ng, Catherine Y and Leung, Wing and Janssen, William E and Wu, Jianrong and Mao, Shenghua and Brennan, Rachel C and Santana, Victor M and Pappo, Alberto S and Furman, Wayne L
Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
by Michael A. Bookman and Mark F. Brady and William P. McGuire and Peter G. Harper and David S. Alberts and Michael Friedlander and Nicoletta Colombo and Jeffrey M. Fowler and Peter A. Argenta and Koen De Geest and David G. Mutch and Robert A. Burger and Ann Marie Swart and Edward L. Trimble and Chrisann Accario-Winslow and Lawrence M. Roth
Journal of Clinical Oncology, ISSN 0732-183X, 03/2009, Volume 27, Issue 9, pp. 1419 - 1425
Purpose To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free survival (PFS) for women with... 
PEGYLATED LIPOSOMAL DOXORUBICIN | 1ST-LINE TREATMENT | ONCOLOGY-GROUP | ONCOLOGY | PRIMARY PERITONEAL CANCER | LONG-TERM SURVIVAL | CLINICAL-TRIALS | RANDOMIZED-TRIAL | PLUS CARBOPLATIN | EPITHELIAL OVARIAN | PACLITAXEL | Peritoneal Neoplasms - pathology | Deoxycytidine - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carboplatin - administration & dosage | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Peritoneal Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Doxorubicin - analogs & derivatives | Topotecan - administration & dosage | Female | Neoplasm Staging | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Doxorubicin - administration & dosage | Index Medicus | Original Reports | Gync19
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice
by Rovida, Alessandra and Castiglioni, Vittoria and Decio, Alessandra and Scarlato, Valentina and Scanziani, Eugenio and Giavazzi, Raffaella and Cesca, Marta
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2013, Volume 12, Issue 10, pp. 2237 - 2247
The development of resistance and progressive disease after treatment with angiogenesis inhibitors is becoming a controversial issue. We investigated the... 
TARGETED THERAPIES | ONCOLOGY | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | BEVACIZUMAB | SUNITINIB | KINASE INHIBITOR | COMBINATION | TUMOR-GROWTH | CANCER | DISEASE PROGRESSION | PACLITAXEL | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Deoxycytidine - administration & dosage | Humans | Indoles - administration & dosage | Carcinoma, Lewis Lung - drug therapy | Cisplatin - administration & dosage | Cell Movement - drug effects | Protein Kinase Inhibitors - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Animals | Neoplasm Invasiveness - pathology | Pyrroles - administration & dosage | Carcinoma, Lewis Lung - pathology | Topotecan - administration & dosage | Mice | Paclitaxel - administration & dosage | Deoxycytidine - analogs & derivatives | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial
by Poveda, Andres M and Selle, Frédéric and Hilpert, Felix and Reuss, Alexander and Savarese, Antonella and Vergote, Ignace and Witteveen, Petronella and Bamias, Aristotelis and Scotto, Nana and Mitchell, Lada and Pujade-Lauraine, Eric
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 32, pp. 3836 - 3838
ONCOLOGY | NEUROBLASTOMA | Prognosis | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Neoplasm Grading | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Bevacizumab - administration & dosage | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Polyethylene Glycols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Aged | Neoplasm Staging | Platinum Compounds - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
by Bradley J. Monk and Michael W. Sill and D. Scott McMeekin and David E. Cohn and Lois M. Ramondetta and Cecelia H. Boardman and Jo Benda and David Cella
Journal of Clinical Oncology, ISSN 0732-183X, 10/2009, Volume 27, Issue 28, pp. 4649 - 4655
Purpose Assess toxicity and efficacy of cisplatin (Cis) doublet combinations in advanced and recurrent cervical carcinoma. Patients and Methods Patients were... 
SQUAMOUS-CELL CARCINOMA | ONCOLOGY | GUIDELINES | TOPOTECAN | TABLES | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Uterine Cervical Neoplasms - pathology | Fatigue - chemically induced | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Leukopenia - chemically induced | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Paclitaxel - adverse effects | Topotecan - adverse effects | Treatment Outcome | Uterine Cervical Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Quality of Life | Topotecan - administration & dosage | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Index Medicus | Original Reports | Gync5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
by Kummar, Shivaani and Chen, Alice and Ji, Jiuping and Zhang, Yiping and Reid, Joel M and Ames, Matthew and Jia, Lee and Weil, Marcie and Speranza, Giovanna and Murgo, Anthony J and Kinders, Robert and Wang, Lihua and Parchment, Ralph E and Carter, John and Stotler, Howard and Rubinstein, Larry and Hollingshead, Melinda and Melillo, Giovanni and Pommier, Yves and Bonner, William and Tomaszewski, Joseph E and Doroshow, James H
Cancer Research, ISSN 0008-5472, 09/2011, Volume 71, Issue 17, pp. 5626 - 5634
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was carried out to determine maximum... 
ADVANCED MALIGNANCIES | DRUG | CELLS | REPAIR | 0 CLINICAL-TRIAL | ONCOLOGY | ADP-RIBOSE POLYMERASE | DNA-DAMAGE | GAMMA-H2AX | TOPOISOMERASE-I | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Topoisomerase I Inhibitors - pharmacokinetics | Drug Administration Schedule | Humans | Middle Aged | Topoisomerase I Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols | Benzimidazoles - pharmacokinetics | Male | Poly(ADP-ribose) Polymerases - administration & dosage | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Lymphoma - drug therapy | Maximum Tolerated Dose | Animals | Benzimidazoles - administration & dosage | Mice, Nude | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Adult | Female | Aged | Mice | Index Medicus | clinical trial | phase I | ABT-888 | PARP inhibitor | topotecan
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Topotecan‐loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers
by Venâncio, João Hélio and Andrade, Lígia Marquez and Esteves, Najla Locatelli Santos and Brito, Lara Barroso and Valadares, Marize Campos and Oliveira, Gisele Augusto Rodrigues and Lima, Eliana Martins and Marreto, Ricardo Neves and Gratieri, Tais and Taveira, Stephânia Fleury
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 10/2017, Volume 69, Issue 10, pp. 1318 - 1326
ObjectivesThis work aimed to evaluate semisolid formulations containing topotecan (TPT) loaded nanostructured lipid carriers (NLC) for topical treatment of... 
hydroxyethylcellulose gel | nanostructured lipid carriers | cytotoxicity and skin permeation | chitosan gel | topotecan | PHARMACOLOGY & PHARMACY | Skin Absorption - physiology | Topoisomerase I Inhibitors - metabolism | Skin Neoplasms - drug therapy | Melanoma, Experimental - drug therapy | Drug Carriers - administration & dosage | Melanoma, Experimental - metabolism | Topotecan - metabolism | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - metabolism | Dose-Response Relationship, Drug | Swine | Hydrogels - administration & dosage | Nanoparticles - metabolism | Skin Absorption - drug effects | Hydrogels - metabolism | Cell Survival - physiology | Organ Culture Techniques | Cell Survival - drug effects | Drug Carriers - metabolism | Topoisomerase I Inhibitors - administration & dosage | Treatment Outcome | Lipids - administration & dosage | Skin Neoplasms - metabolism | Animals | Topotecan - administration & dosage | Mice | Nanoparticles - administration & dosage | Administration, Topical | Nanoparticles | Chemotherapy | Dermatology | Melanoma | Formulae, receipts, prescriptions | Cellulose | Dermatologic agents | Skin | Drug therapy | Skin cancer | Cancer | Formulations | Cell culture | Gels | Hydrogels | Toxicity | Cytotoxicity | Topotecan | Dispersions | Penetration | Chitosan | Semisolids | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial
by Keefe, S.M and Hoffman-Censits, J and Cohen, R.B and Mamtani, R and Heitjan, D and Eliasof, S and Nixon, A and Turnbull, B and Garmey, E.G and Gunnarsson, O and Waliki, M and Ciconte, J and Jayaraman, L and Senderowicz, A and Tellez, A.B and Hennessy, M and Piscitelli, A and Vaughn, D and Smith, A and Haas, Naomi B
Annals of Oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1579 - 1585
The combination of the campothecan-containing nanoparticle-drug conjugate, CRLX101 and bevacizumab is well tolerated, safe, and active in a heavily pretreated... 
Hypoxia-inducible factor | Angiogenesis | CRLX101 | Recommended phase II dose | Nanoparticle-drug conjugate | Renal cell carcinoma | renal cell carcinoma | nanoparticle-drug conjugate | EVEROLIMUS | ONCOLOGY | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | angiogenesis | recommended phase II dose | TOPOTECAN | hypoxia-inducible factor | CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cyclodextrins - adverse effects | Nanoparticles - chemistry | Antineoplastic Combined Chemotherapy Protocols - chemistry | Bevacizumab - adverse effects |